Skip to main content
Clinical Trials/JPRN-UMIN000045075
JPRN-UMIN000045075Completed未知

A Study on the factors associated with continuing treatment with brexpiprazole in patients with schizophrenia using MENTAT - A Study on the factors associated with continuing treatment with brexpiprazole in patients with schizophrenia using MENTAT

Otsuka Pharmaceutical Co., Ltd.0 sites37,534 target enrollmentStarted: August 20, 2021Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Enrollment
37,534

Study Overview

Brief Summary

Eight factors were extracted from the results of multivariate analysis using the Cox proportional hazards regression model. Of these, "symptoms other than positive symptoms (after 28 days)," "ECT," "time of BRX 2 mg dose increase," "key person (with contact information)," and "reports and crimes" had hazard ratios of 1 or greater, while "physical complications," "maximum pre-start CP-equivalent dose category 1 (200-400 mg)" and "hospital days" had hazard ratios less than 1.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18years-old to ot applicable (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1) Patients with mood [affective] disorder, dementia, disorders of psychological development, or hyperactivity disorder at the time of Index date 2) Patients who have been treated with brexpiprazole less than 1 mg / day and more than 2 mg / day even once

Investigators

Similar Trials